Free Design Audit Available - Click Here for Details

Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain

Patent portfolio with over 100 patents, issued and pending, protects technology targeting a $100 billion market opportunity

THE WOODLANDS, TX, April 16, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent 10,143,419 (‘419 patent) entitled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.”

The issued patent is directed to technology including, but not limited to, systems, methods and devices for interventionally treating cancerous tumors and cancer related pain. The Company is initially advancing the development of its technology to address pancreatic cancer-related pain.

Sign up for Blog Updates